Qiagen N.V. QGEN
Set alert
As of Nov 2, 3:52 PM ET
- YTD
- +12.11%
- 1 year
- +7.61%
- Open
- 50.50
- Prev close
- 50.22
- Mkt cap
- 10.40B
- Vol
- 3.04M
- Avg vol
- 3.60M
- EPS
- 1.97
- P/E
- 25.58
- Div yield
- 0.70%
More statistics
- Low
- 50.31
- High
- 50.50
- Forward P/E
- 19.21
- Beta
- 0.61
- Short ratio
- 3.34
- Inst. own
- 79.42%
- Dividend
- 0.35
- Ex-div date
- Jul 6, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 45.00
- 200-d avg
- 42.58
- 1y target
- 49.02
5D chart
Events in this range
- Oct 28, 2026Downgrade: Barclays · Overweight → Equal-Weight
Signals (73)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 11:40 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 11:40 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 11:30 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 11:30 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 11:20 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:15 AM | 5 hours ago |
| RSI: Overbought | Nov 2, 10:05 AM | 5 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 6 hours ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 5 days ago |
| RSI: Oversold | Oct 27, 3:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 6 days ago |
| RSI: Oversold | Oct 27, 2:55 PM | 6 days ago |
| RSI: Oversold | Oct 27, 2:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 10:40 AM | 6 days ago |
News
2 days ago zacks.com
Do Options Traders Know Something About Qiagen Stock We Don't?
Investors need to pay close attention to QGEN stock based on the movements in the options market lately.
5 days ago zacks.com
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
BALA CYNWYD, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
-
5 days ago benzinga.com
Barclays Downgrades Qiagen to Equal-Weight, Lowers Price Target to $53
Barclays analyst Luke Sergott downgrades Qiagen (NYSE:QGEN) from Overweight to Equal-Weight and lowers the price target from $55 to $53.
5 days ago 247wallst.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Enphase Energy, F5, Marvell Technology, MSG Rangers, Pentair, Silicon Motion Technology, Spotify Technology, Texas Instruments, Whirlpool, and More
With the Fed rate decision dropping at 2:30 PM and Alphabet and Microsoft reporting before the bell, Wednesday's analyst calls on Enphase, Spotify, Whirlpool, and a newly public Rangers franchise…
-
1 week ago benzinga.com
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $52
Citigroup analyst Albert Hu maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $45 to $52.
1 week ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
BALA CYNWYD, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
1 week ago benzinga.com
Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing
Qiagen agrees to a $12 billion all-cash buyout by EQT. Analysts view the valuation discount as warranted given slower growth.
1 week ago benzinga.com
This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
1 week ago benzinga.com
This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Analysts downgraded Qiagen, Alcoa and Dutch Bros, cutting price targets for Qiagen to $52 and Dutch Bros to $46.
-
1 week ago benzinga.com
JP Morgan Downgrades Qiagen to Neutral, Lowers Price Target to $52
JP Morgan analyst Casey Woodring downgrades Qiagen (NYSE:QGEN) from Overweight to Neutral and lowers the price target from $55 to $52.
1 week ago businesswire.com
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of QIAGEN N.V. (NYSE: QGEN) to the EQT XI fund for €46.50 in cash per share.Halper Sadeh encourages…
1 week ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Block, Constellation Energy, Dick’s Sporting Goods, Dutch Bros, Halliburton Company, Netflix, Southern Company,Tesla, and More
Wall Street analysts are reshuffling their bets on Tesla, Netflix, and Dutch Bros while SpaceX's blowout earnings send futures sliding ahead of the open. Find out which names got upgraded,…
-
1 week ago benzinga.com
Baird Maintains Outperform on Qiagen, Raises Price Target to $52
Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $50 to $52.
-
1 week ago benzinga.com
QIAGEN Reports Preliminary Q3 Net Sales Of $548M; Preliminary Q3 Adj EPS $0.65; Co. Suspends FY 2026 Outlook While Transaction With EQT Private Equity Is Pending
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates…
-
1 week ago benzinga.com
Qiagen And EQT Private Equity Agree On An All-Cash Public Takeover Offer For All Outstanding Qiagen Shares At An Offer Price Of €46.50 Per Share, A Premium Of 40.3% To The Unaffected Share Price; Closing Expected In Mid-2027
QIAGEN and EQT Private Equity agree on an all-cash public takeover offer for all outstanding QIAGEN shares at an offer price of €46.50 per share, a premium of 40.3% to the unaffected share…
1 week ago businesswire.com
QIAGEN reports preliminary Q3 2026 results
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548…
1 week ago businesswire.com
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
VENLO, Netherlands & AMSTERDAM--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an…
1 week ago defenseworld.net
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.93 According to Brokerages
Shares of Qiagen N.V. (NYSE: QGEN - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are presently covering the stock, Marketbeat.com reports.…
1 week ago reuters.com
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
European molecular testing company Qiagen is in advanced talks to be acquired by Swedish buyout firm EQT, Bloomberg News reported on Tuesday, citing people familiar with the matter.
-
1 week ago benzinga.com
'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg
-Bloomberg.
1 week ago defenseworld.net
15,494 Shares of Qiagen N.V. $QGEN Bought by Cordatus Wealth Management LLC
Cordatus Wealth Management LLC acquired a new stake in Qiagen N.V. (NYSE: QGEN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The…
2 weeks ago businesswire.com
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the…
3 weeks ago businesswire.com
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help…
-
3 weeks ago benzinga.com
Barclays Upgrades Qiagen to Overweight, Raises Price Target to $55
Barclays analyst Luke Sergott upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight and raises the price target from $40 to $55.
1 month ago zacks.com
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
1 month ago defenseworld.net
Qiagen N.V. $QGEN Shares Sold by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. cut its holdings in Qiagen N.V. (NYSE: QGEN) by 4.8% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor…
-
1 month ago benzinga.com
FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker
Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deathsNew QIAstat-Dx test…
1 month ago businesswire.com
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete…
1 month ago defenseworld.net
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51
Qiagen N.V. (NYSE: QGEN - Get Free Report) has been given an average rating of "Hold" by the fourteen brokerages that are covering the company, Marketbeat reports. Nine analysts have rated the stock…
1 month ago businesswire.com
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample…
2 months ago benzinga.com
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.
-
2 months ago benzinga.com
10x Genomics Wins Patent Case Against Parse Biosciences As Jury Finds Willful Infringement And Awards $4.8M+ In Damages; Company To Seek Enhanced Damages, Fees And Permanent Injunction
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life…
-
2 months ago benzinga.com
QIAGEN Appoints Jonathan M. Pratt CEO, Effective Sept. 1, Succeeding Thierry Bernard; Co. Reiterates Q3, FY26 Guidance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than…
-
2 months ago benzinga.com
QIAGEN Says FDA Clears QIAstat-Dx BCID GPF Plus AMR Panel For Bloodstream Infections
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hourFDA clearance marks QIAGEN's entry into U.S.…
-
2 months ago benzinga.com
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $45
Citigroup analyst Brendan Digan maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $38 to $45.
-
2 months ago benzinga.com
Barclays Maintains Equal-Weight on Qiagen, Raises Price Target to $40
Barclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and raises the price target from $38 to $40.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50
JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $45 to $50.
-
2 months ago benzinga.com
Conference Call: Qiagen Q3 Adj EPS expected to be more than $0.62 vs $0.64 Est; Sees Q3 Sales $538.330M-$543.660M vs $552.590M Est
Qiagen (NYSE:QGEN) Q3 expected to be more than $0.62 vs $0.64 Est. sees Q3 sales of $538.330 million-$543.660 million vs $552.590 million analyst estimate.
-
2 months ago benzinga.com
Qiagen FY2026 Adj EPS expected to be more than $2.43 vs $2.42 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.139B Est
Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.43 vs $2.42 Est. affirms FY2026 sales outlook from $2.111 billion-$2.132 billion to $2.111 billion-$2.132 billion vs $2.139 billion estimate.
-
2 months ago benzinga.com
Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate
Qiagen (NYSE:QGEN) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.60 by 3.33 percent. This is a 8.77 percent increase over earnings of $0.57 per share…
-
3 months ago benzinga.com
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens Menu
More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwideQIAGEN’s FDA-cleared QIAstat-Dx…
3 months ago benzinga.com
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
-
4 months ago benzinga.com
Morgan Stanley Upgrades Qiagen to Overweight, Raises Price Target to $42
Morgan Stanley analyst Steve Beuchaw upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight and raises the price target from $40 to $42.
-
4 months ago benzinga.com
QIAGEN Expands QIAcuity Digital PCR Portfolio Into Gene Expression, Cell And Gene Therapy And Automated Workflows To Drive Broader Adoption Across Life Sciences
Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areasExpanded Cell and Gene Therapy…
-
5 months ago benzinga.com
Qiagen Announces That QIAGEN Digital Insights Bioinformatics Business And Its Curated Knowledge Bases And Bioinformatics Expertise Will Be Integrating NVIDIA Accelerated Computing And The NVIDIA Bionemo Platform To Help Researchers Use AI More Effectively In Drug Discovery
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge…
-
5 months ago benzinga.com
Stifel Maintains Hold on Qiagen, Lowers Price Target to $36
Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target from $50 to $36.
-
5 months ago benzinga.com
QIAGEN's 2026 AGM To Feature 40% Dividend Increase To $0.35/Share, $200M Buyback And Co-Founder Colpan As Honorary Chairman
Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-electionRobert McMahon nominated for election to Supervisory Board…
-
5 months ago benzinga.com
TD Cowen Maintains Hold on Qiagen, Lowers Price Target to $40
TD Cowen analyst Dan Brennan maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target from $46 to $40.
-
5 months ago benzinga.com
QIAGEN Plans To Advance QuantiFERON Latent TB Test With Automated Sample To Insight Workflow And Separate AI-Enabled Risk Stratification Tool For TB Progression
Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to growFully automated workflow targeted for late 2027 launch…